To further validate the findings observed in the AML12 cell model of NAFLD, we established a NAFLD mouse model to test the hepatoprotective and lipid-lowering effects of gardenoside and CTCF silencing. This evidence concerns the gene CTCF and metabolic dysfunction-associated steatotic liver disease.